Due to system upgrades, please note the following. Orders can be placed in the online store but will be fulfilled after 7/14/2025. Learning activities ordered will be available immediately after order placement. CAP is committed to processing orders as quickly and securely as possible during this upgrade. Thank you for your patience.
Please log in to determine if you are eligible to purchase PT Programs.
HLA DRUG HYPERSENSITIVITY - PGX2
PGX2
Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).
Analyte/Procedure
Challenges per Shipment
Number of Shipments
HLA‑B*15:02
3
Two shipments per year
HLA‑B*57:01
3
Additional Information
Designed for laboratories that provide HLA‑B*57:01 testing to identify risk of hypersensitivity to abacavir and HLA-B*15:02 testing to identify risk of hypersensitivity to carbamazepine. The intended response is qualitative (presence/absence of the allele). This Survey is not appropriate for laboratories that perform molecular HLA typing. For HLA typing proficiency testing, please consult the HLA Molecular Typing (DML) Survey.
Program Information
Three 25.0‑μg extracted DNA specimens
Includes allele detection (genotyping) and/or interpretive challenges
Help